Department of Surgery, Kochi Medical School, Kochi, Japan
Department of Surgery, Kochi Medical School, Kochi, Japan.
Anticancer Res. 2014 Sep;34(9):5067-74.
Synchronous primary gastric adenocarcinoma and lymphoma is a rare occurrence. The aim of the present retrospective study was to analyze the clinicopathological characteristics and therapeutic outcomes of patients with this rare condition to identify post-therapeutic prognostic factors.
A PubMed and MEDLINE search was performed to identify relevant articles, using the keywords 'gastric cancer' and 'gastric malignant lymphoma', while additional articles were obtained from references within these papers. A total of 57 patients who were treated for synchronous primary gastric adenocarcinoma and lymphoma were included in the study. A retrospective review was performed on the clinical characteristics of this disease.
The median survival time for patients in this study was 81 months and the overall 1- and 5-year survival rates after therapy were 77.6% and 69.0%, respectively. The median survival period of patients with an advanced gastric cancer was significantly shorter than for early gastric cancer (p<0.001), while the depth of gastric lymphoma invasion did not significantly affect survival time. The median survival period of patients who underwent total gastrectomy was significantly shorter than that of those who underwent distal gastrectomy (p=0.035). Gastric lymphomas were significantly larger than the gastric adenocarcinomas (6.0 vs. 2.7 cm, respectively; p=0.012).
The prognosis for synchronous gastric adenocarcinoma and lymphoma might depend more on the behavior of the adenocarcinoma than on the lymphoma, in which case the treatment and therapeutic outcomes could depend on the adenocarcinoma status.
同步原发性胃腺癌和淋巴瘤是一种罕见的情况。本回顾性研究旨在分析此类罕见疾病患者的临床病理特征和治疗结果，以确定治疗后的预后因素。
通过在 PubMed 和 MEDLINE 上使用“gastric cancer”和“gastric malignant lymphoma”关键词进行检索，以确定相关文章，并从这些论文中的参考文献中获取其他文章。本研究共纳入 57 例同步原发性胃腺癌和淋巴瘤患者。对该疾病的临床特征进行了回顾性分析。
本研究中患者的中位生存时间为 81 个月，治疗后 1 年和 5 年的总生存率分别为 77.6%和 69.0%。晚期胃癌患者的中位生存时间明显短于早期胃癌（p<0.001），而胃淋巴瘤浸润深度并不显著影响生存时间。行全胃切除术的患者中位生存时间明显短于行远端胃切除术的患者（p=0.035）。胃淋巴瘤明显大于胃腺癌（分别为 6.0 cm 和 2.7 cm，p=0.012）。
同步胃腺癌和淋巴瘤的预后可能更多地取决于腺癌的行为，而不是淋巴瘤，在这种情况下，治疗和治疗结果可能取决于腺癌的状态。
